{‘She has zero qualifications’: this US scientific establishment girds for Dr. Høeg's role at the FDA.

Given that the United States continues making sweeping adjustments to its vaccine guidelines, one figure appears in a surprising turn: Dr. Tracy Beth Høeg, a Danish American sports physician and public health researcher who initially gained attention by questioning COVID-19 vaccines in the global health crisis and has focused upon potential fatalities after COVID-19 vaccination in her brief tenure at the US Food and Drug Administration (FDA).

Planned Shifts to Pediatric Immunization Schedule

Agency leaders had intended to announce major revisions to the pediatric vaccination calendar earlier this month, aligning the US with Denmark’s national calendar, sources say – a major change that would place the US out of alignment with a large portion of the international standard with insufficient data for benefit. This reveal has been pushed back until the new year.

In place of Vinay Prasad, Dr. Høeg is set to speak at the meeting. She was just designated temporary leader of the FDA’s CDER, the fifth appointee to lead the center this calendar year.

A New Direction at the Agency

Høeg's temporary position might represent a tighter collaboration between the pharmaceutical and biologics centers as Høeg and Dr. Prasad solidify control at the FDA – and it suggests a increased emphasis upon dismantling already-approved vaccines at the FDA.

Dr. Høeg has often pushed for halting specific childhood immunization guidelines in the US to become more like Denmark, a society with comprehensive healthcare and a population roughly the size of Wisconsin’s.

So far public appearances, she has kept her attention on vaccination policy – typically the responsibility of Dr. Prasad, head of the FDA’s vaccine center – instead of pharmaceutical oversight.

Questions Over Qualifications

Dr. Høeg has no apparent experience in pharmaceutical research, regulation or management, which has been customary for past heads of the Center for Biologics Evaluation and Research. She has been employed at the FDA as a key advisor to the commissioner and CBER since March.

“It seems she lacks to have the requisite experience” for overseeing the pharmaceutical oversight division, said Dr. Jonathan Howard. “She has not conducted a scientific study. She lacks experience in managing a major agency. She is not an expert in pharmaceutical oversight.”

Former directors of the center would “understand regulatory frameworks and the research of pharmaceutical innovation”, said a former acting FDA commissioner. “Clearly, she doesn’t have the sort of resume that prior appointees who ran CBER have had.”

This division has an vast workload at the FDA, she pointed out.

“Many people just pays attention on the innovative therapies, but the generic drug division clears numerous generic medications. There’s a biosimilars division, over-the-counter program and so forth, and each of these have to be supervised,” Dr. Woodcock noted. “The responsibility you overlook, that is the part that I always told people is going to come back to haunt you.”

Furthermore, a substantial management component to the job, which oversees in excess of 5,000 employees. “It is a massive management job, if you perform it correctly,” she said.

Response and Contentious Initiatives

Regarding questions about Høeg’s qualifications and whether this assignment represents increased cooperation among FDA leaders on vaccines, a press secretary responded that the “questions are based on flawed presumptions”.

“This background aligns with the responsibilities of her position,” the official stated, noting the months Dr. Høeg spent counseling the agency head on “medication safety and regulatory science, including computerized risk analysis and immunization monitoring”.

As the temporary head, Høeg takes over the agency head's recently launched priority voucher program, a contentious expedited drug-approval program that apparently worried her predecessors. “How are these therapies being chosen for this fast-track system? Who makes the calls?” Howard asked. “There is a lot of lack of transparency happening at the regulatory body right now.”

In general, he stated, “the FDA looks to be trending towards more relaxed oversight of all drugs, except for shots.”

Public Past Work on Vaccines

Regarding immunizations, Dr. Høeg has a clearer, if troubling, track record, Howard observe. She released a analysis using unverified volunteer-provided data to determine the incidence of myocarditis after Covid vaccination. She consulted for the Florida surgeon general Joseph Ladapo, who allegedly have changed statistics to indicate Covid vaccines are riskier than they are.

Among her “policy goals” for the new government encompassed revising regulations for novel immunizations and ending “non-essential” immunizations, she remarked post-election on a online show. At the FDA, Høeg has according to sources proposed preventing teenage boys from obtaining COVID-19 vaccines.

“She’s an all-around ideologue who commences with her conclusions and works backwards to fit the evidence in a extremely deceptive, dishonest fashion,” Howard said.

Taking Control and a “Push for Payback”

Dr. Høeg joined fellow skeptics, {like|